ClinicalTrials.gov
ClinicalTrials.gov Menu

Expression of Optic Atrophy Type 1 (OPA1) Protein in Lung Adenocarcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01249053
Recruitment Status : Unknown
Verified November 2010 by China Medical University Hospital.
Recruitment status was:  Recruiting
First Posted : November 29, 2010
Last Update Posted : November 29, 2010
Sponsor:
Information provided by:
China Medical University Hospital

Brief Summary:
Optic atrophy type 1(OPA1) is a nuclear dynamin-related GTPase, targeted to the inner mitochondrial membrane, which plays a role in mitochondrial fusion. Mitochondria fusion is associated with process of apoptosis. . OPA1 plays an important role in the mitochondrial bioenergetics and mitochondrial networks. The changes in mitochondrial shape and mitochondrial bioenergetics may be cause of the disease. In this study, we investigate the expression of OPA1 in lung adenocarcinoma (LADC) cells and tissue.

Condition or disease
Lung Adenocarcinoma

Study Type : Observational
Estimated Enrollment : 100 participants
Time Perspective: Retrospective
Study Start Date : August 2010






Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   25 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Between January 2006 and December 2008, we will retrospectively enroll 100 consecutive LADC patients who were admitted to the Department of Thoracic Surgery of China Medical University Hospital.
Criteria

Inclusion Criteria:

  • We will collect paraffin blocked resected lung tissue samples from stage I~IIIa non-small cell lung cancer patients (age, 40~80 years old) who received lobectomy of the affected lung.

Exclusion Criteria:

  • History of uremia, other malignant disease, and liver cirrhosis
  • History of pneumonia and pulmonary tuberculosis
  • History of long period of medications.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01249053


Locations
Taiwan
Fang Hsin Yuan Recruiting
Taichung, Taiwan, 404
Contact: Hsin-Yuan Fang, MD    +886422052121 ext 1638    d93421104@ntu.edu.tw   
Sponsors and Collaborators
China Medical University Hospital

Responsible Party: Fang Hsin-Yuan/Director, China Medical University Hospital
ClinicalTrials.gov Identifier: NCT01249053     History of Changes
Other Study ID Numbers: DMR99-IRB-062
First Posted: November 29, 2010    Key Record Dates
Last Update Posted: November 29, 2010
Last Verified: November 2010

Keywords provided by China Medical University Hospital:
OPA1
lung adenocarcinomas
Prognosis
Expression of optic atrophy type 1 (OPA1) protein in lung adenocarcinoma

Additional relevant MeSH terms:
Adenocarcinoma
Lung Neoplasms
Optic Atrophy
Optic Atrophy, Autosomal Dominant
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Optic Nerve Diseases
Cranial Nerve Diseases
Nervous System Diseases
Eye Diseases
Optic Atrophies, Hereditary
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Eye Diseases, Hereditary
Genetic Diseases, Inborn
Mitochondrial Diseases
Metabolic Diseases